-
Posted by
Two Blokes Jul 8 -
Filed in
Stock
-
5 views
FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy, providing a major competitive advantage over injectable options. EKTERLY's convenience and rapid symptom relief position it for strong market adoption, with a $4 billion HAE market opportunity and potential to shift on-demand market share. Global expansion is underway, with seven regulatory submissions, and if approved for these territories, it could increase the amount of revenues that are to be generated.
